KIBRA; a novel biomarker predicting recurrence free survival of breast cancer patients receiving adjuvant therapy

• Main Authors: Lakmini Mudduwa, Harshini Peiris, Shania Gunasekara, Deepthika Abeysiriwardhana, Nimsha Liyanage, Suresh K. Rayala, Thusharie Liyanage
• Format: Article
• Language: English
• Published: BMC 2018-05-01
• Series: BMC Cancer
• Subjects: ER; Endocrine therapy; Breast cancer; KIBRA; Recurrence free survival
• Online Access: http://link.springer.com/article/10.1186/s12885-018-4491-6

Abstract Background This study was carried out to evaluate the prognostic value of KIBRA in breast cancer. Methods This retrospective study included breast cancer patients who sought the services of the immunohistochemistry laboratory of our unit from 2006 to 2015. Tissue microarrays were constructed and immunohistochemical staining was done to assess the KIBRA expression. The Kaplan-Meier model for univariate and Cox-regression model with backward stepwise factor retention method for multivariate analyses were used. Chi square test was used to find out the associations with the established prognostic features. Results A total of 1124 patients were included in the study and KIBRA staining of 909 breast cancers were available for analysis. Cytoplasmic KIBRA expression was seen in 39.5% and nuclear expression in 44.8%. Overall KIBRA–low breast cancers accounted for 41.5%. KIBRA nuclear expression was significantly associated with positive ER and PR expression. Luminal breast cancer patients who had endocrine therapy and KIBRA-low expression had a RFS disadvantage over those who were positive for KIBRA (p = 0.02). Similarly, patients who received chemotherapy and had overall KIBRA-low expression also demonstrated a RFS disadvantage compared to those who had overall positive KIBRA expression (p = 0.018). This effect of KIBRA was independent of the other factors considered for the model. Conclusion Overall low-KIBRA expression has an independent effect on the RFS and predicts the RFS outcome of luminal breast cancer patients who received endocrine therapy and breast cancer patients who received chemotherapy.